The research focuses on peripheral afferent neurons, specialized nerve fibers responsible for transmitting sensory information from body tissues to the central nervous system. These neurons are known to invade osteosarcoma tumors, where their interaction creates a microenvironment that not only exacerbates pain but also supports tumor innervation and angiogenesis, fostering unchecked malignancy growth. Using sophisticated murine models genetically engineered to suppress key neuron growth pathways, the study uncovers the pivotal role played by proteins—nerve growth factor (NGF), its receptor tropomyosin receptor kinase-A (TrkA), and calcitonin gene-related peptide (CGRP)—in mediating this pathological crosstalk.

The authors demonstrate that pharmacological blockade of NGF-TrkA signaling via the application of bupivacaine and rimegepant—drugs already sanctioned by the FDA for nerve pain and migraine management, respectively—substantially diminishes tumor-associated nerve sprouting as well as the vascular networks vital for tumor sustenance. This suppression not only alleviates the debilitating pain affecting osteosarcoma patients but crucially retards tumor proliferation and metastatic dissemination. The findings redefine the therapeutic landscape, underscoring the potential of targeting peripheral neurobiology to combat bone cancer.

Intriguingly, the team’s previous research had established that enhancement of NGF-TrkA signaling facilitates bone fracture repair by promoting nerve and blood vessel growth. This new study, however, reveals a paradox wherein the very pathway that aids skeletal healing becomes hijacked by malignant cells to foster their expansion. Aaron James, M.D., Ph.D., senior author and professor of pathology at Johns Hopkins, emphasizes that therapeutic strategies must therefore be context-dependent, shifting from stimulation in regenerative settings to inhibition in oncogenic ones.

Using genetically modified mice lacking functional TrkA signaling in sensory neurons, the team showed a marked reduction in tumor innervation and angiogenesis compared to controls. These TrkA-deficient mice exhibited slower tumor growth rates and extended survival, reinforcing the causal link between peripheral nerve activity and osteosarcoma pathogenesis. Beyond the neural landscape, the study noted a concomitant decline in tumor-associated macrophages—immune cells that contribute to a pro-tumor microenvironment by suppressing immune responses and aiding resistance to chemotherapy.

Human tumor samples echoed the murine findings by displaying increased expression of NGF-TrkA signaling components correlated with extensive nerve and vessel growth within osteosarcomas. This correlation validates the translational relevance of the mouse model and supports the notion that peripheral nerves actively shape tumor behavior in patients. Further analysis of dorsal root ganglion neurons — integral to relaying sensory signals from peripheral tissues — from individuals experiencing tumor-related pain revealed elevated CGRP activity alongside inflammatory markers, reinforcing the signaling axis as a candidate for therapeutic intervention.

Building upon these insights, the researchers administered bupivacaine and rimegepant to their osteosarcoma-bearing mice, observing significant reductions in neural and vascular tumor infiltration. These drugs, by disabling CGRP and NGF-TrkA signaling pathways, disrupt the neuron-to-tumor communication loop that amplifies malignancy. Consequently, treated mice manifested reduced tumor burden and decreased nociceptive behavior, suggesting dual benefits in cancer control and pain management.

The study’s revelation that peripheral sensory neurons are indispensable components in osteosarcoma development and symptomatology shifts paradigms in cancer biology. It unites neurobiology with oncology in a deeply mechanistic framework, illustrating how tumors co-opt physiological nerve signaling pathways to orchestrate their own growth niches. Future research aims to delineate the molecular underpinnings of neuron-tumor interactions further, potentially identifying new molecular targets alongside TrkA and CGRP to interrupt this pathogenic dialogue.

Funding for this research was provided by an extensive array of federal sources including multiple grants from the National Institutes of Health—specifically the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Neurological Disorders and Stroke, and the National Institute of Dental and Craniofacial Research—as well as support from the Department of Defense and prominent cancer and stem cell research foundations. Collaborative contributions extended across Johns Hopkins, Memorial Sloan Kettering Cancer Center, University of Maryland, University of Texas at Dallas, University of Texas Southwestern, and University of Wisconsin-Madison, embodying a truly multidisciplinary approach.

Beyond its scientific novelty, this work carries profound clinical implications. Current osteosarcoma treatments often involve aggressive surgical interventions and chemotherapy with limited success against metastatic disease and nerve pain. By repurposing already-approved medications that target nerve-cancer interactions, clinicians may soon have new tools to both stanch tumor growth and improve quality of life for patients suffering from severe cancer-induced pain. This study thus paves the way for translational efforts aiming to bridge basic discoveries with concrete therapeutic strategies.

Ultimately, the research underscores the intricate interplay between the nervous system and cancer biology, revealing peripheral neurons as key facilitators of malignancy rather than mere bystanders. By targeting this critical nexus with analgesic drugs, the field may witness the emergence of novel, less toxic therapeutic paradigms that leverage the body’s own signaling machinery to combat cancer.

Subject of Research: Interaction of peripheral sensory neurons with osteosarcoma tumor growth and associated pain mechanisms

Article Title: Peripheral sensory nerve signaling blockade impedes osteosarcoma growth and relieves tumor-associated pain

News Publication Date: October 28, 2025

Web References: https://doi.org/10.1073/pnas.2500161122

Image Credits: Sowmya Ramesh, Johns Hopkins Medicine

Keywords: Cancer, Bone cancer, Osteosarcoma, Peripheral nerves, NGF-TrkA signaling, Calcitonin gene-related peptide, Tumor innervation, Angiogenesis, Pain management, Bupivacaine, Rimegepant

Prostate cancer, long targeted primarily through therapies aimed at the androgen receptor (AR), often evolves into forms that no longer depend on this signaling pathway, thereby rendering these treatments ineffective. The process of lineage plasticity—where cancer cells alter their identity and become resistant to hormonal therapies—poses a significant clinical challenge. This new research, led by senior author Dr. Joshi J. Alumkal and spearheaded by Zhi Duan, Ph.D., elucidates a molecular driver behind this change, offering hope for patients grappling with aggressive prostate tumors that have outmaneuvered existing treatment modalities.

Their investigation unveiled PROX1 as an early and critical marker in the transformation from androgen receptor-dependent prostate cancer to its more aggressive, androgen receptor-independent subtypes, including double-negative prostate cancer and neuroendocrine prostate cancer. Notably, PROX1 expression was found to increase sharply in tumor cells that lost AR activity, correlating with more aggressive disease phenotypes. By analyzing hundreds of patient tumor biopsies along the lineage plasticity continuum, the researchers established PROX1 not only as a biomarker but as a possible causal agent facilitating the malignant reprogramming of prostate cancer cells.

At a mechanistic level, PROX1 acts as a transcription factor, a protein that binds DNA and controls the expression of other genes, effectively orchestrating the identity and behavior of cancer cells. The study demonstrated an inverse relationship between PROX1 and the androgen receptor across patient tumor datasets, suggesting that PROX1 may actively repress AR expression and function. Experimentally, forcing PROX1 expression in prostate cancer cells resulted in downregulation of AR, reinforcing the idea that PROX1 suppresses AR-driven pathways, fostering cellular plasticity and progression towards treatment-resistant states.

Genetic ablation experiments, which selectively knocked out PROX1 from double-negative and neuroendocrine prostate cancer cells, resulted in significant growth arrest and increased cell death. This evidence firmly supports the notion that PROX1 is not merely a passenger in lineage plasticity but a driver essential for the survival and proliferation of aggressive prostate cancer subtypes. However, the challenge lies in targeting PROX1 pharmacologically, as transcription factors historically have proven difficult to inhibit directly with drugs.

Pivoting around this obstacle, the researchers uncovered a promising indirect strategy by investigating proteins that interact with PROX1. Among these cofactors, histone deacetylases (HDACs) stood out as significant partners. HDACs are enzymes that modify chromatin structure and regulate gene expression and have been successfully targeted in other cancer types with approved inhibitors. Hypothesizing a cooperative relationship, the team tested whether inhibiting HDAC activity could disrupt PROX1 function.

Their results were striking. Treatment of PROX1-expressing prostate cancer cells with HDAC inhibitors led to a notable reduction in PROX1 protein levels, mirroring the effects observed with genetic deletion. As PROX1 diminished, cell viability decreased dramatically, indicating that HDAC inhibitors can thwart the survival mechanisms of these aggressive cancer cells by destabilizing PROX1. Given that HDAC inhibitors are already clinically approved for several cancers, these findings open immediate avenues for repurposing these drugs to combat prostate cancer subtypes prone to lineage plasticity.

This discovery carries profound implications for the future management of prostate cancer. By identifying PROX1 as an early driver of lineage plasticity and establishing a link between PROX1 and HDACs, the study provides a molecular rationale for clinical trials testing HDAC inhibitors in patients with aggressive, androgen receptor-independent prostate cancer. Such trials could herald a new therapeutic frontier for individuals currently facing limited options and poor prognoses.

The research conducted at the University of Michigan Rogel Cancer Center involved a multidisciplinary team of experts spanning molecular biology, oncology, and translational medicine. Utilizing patient-derived tumor biopsies, sophisticated genetic manipulation techniques, and advanced cellular assays, the investigators meticulously mapped PROX1’s role in prostate cancer evolution. Their integrative approach underscores the importance of combining genetic insights with pharmacological innovations to tackle complex, treatment-resistant malignancies.

While the study highlights a promising therapeutic target, further research is necessary to delineate the precise molecular pathways by which PROX1 and HDACs interact and regulate prostate cancer cell fate. It also raises intriguing possibilities about whether similar lineage plasticity mechanisms operate in other cancers, potentially broadening the impact of these findings. Moreover, identifying biomarkers that predict response to HDAC inhibition in prostate cancer patients will be critical for translating these discoveries into clinical benefit.

In addition to advancing fundamental knowledge, this work emphasizes the power of “guilt by association” in drug targeting—leveraging the interactions of untargetable proteins like PROX1 with druggable partners such as HDACs. This conceptual framework could transform how researchers approach other intractable oncogenic drivers in cancer biology, accelerating the development of effective therapies where none currently exist.

As the field anticipates clinical trials informed by this study, patients and clinicians alike have renewed optimism that understanding lineage plasticity at the genetic and epigenetic levels will unlock new keys to controlling and, ultimately, overcoming aggressive prostate cancer. The convergence of molecular biology, genomics, and pharmacology displayed in this research exemplifies the promise of precision medicine in oncology.

This seminal study, entitled “PROX1 is an Early Driver of Lineage Plasticity in Prostate Cancer,” appeared in the Journal of Clinical Investigation and represents a significant stride toward identifying novel intervention points in the fight against one of the most challenging forms of cancer progression. The collaboration between genetic analysis and therapeutic innovation showcased here illustrates how tackling the molecular roots of cancer can translate into tangible clinical advances.

In summary, the identification of PROX1 as a central regulator of prostate cancer lineage plasticity and its functional suppression via HDAC inhibitors heralds an exciting development in cancer research. By potentially repurposing existing drugs to inhibit this newly characterized pathway, the study charts a viable route to counteract treatment-resistant prostate cancer and improve patient outcomes in an area of urgent unmet medical need.

Subject of Research: Cells

Article Title: PROX1 is an early driver of lineage plasticity in prostate cancer

News Publication Date: 2-Jun-2025

References: “PROX1 is an Early Driver of Lineage Plasticity in Prostate Cancer,” Journal of Clinical Investigation

Image Credits: Image courtesy of Michael C. Haffner, M.D., Ph.D., Fred Hutchinson Cancer Center

Keywords: Cancer, Prostate cancer